The stock market valuation of R&D information in biotech firms

Contemporary Accounting Research

Volumn 24, Issue 4, 2007, Pages 1291-1318

  Xu, Bixia ^a   Magnan, Michel L ^b   André, Paul E ^c  

^a WILFRID LAURIER UNIVERSITY   (Canada)

^b Gina Cody School of Engineering and Computer Science

^c ESSEC BUSINESS SCHOOL   (France)

Author keywords

Predictive ability; R D expenditures; Uncertainty; Value relevance

Indexed keywords

EID: 37549016020     PISSN: 08239150     EISSN: 19113846     Source Type: Journal    
DOI: 10.1506/car.24.4.10     Document Type: Article

References (44)

1. Agnew, B. 2000. When pharma merges, R&D is the dowry. Science 287: 1952-3.
2. Al-Horani, A., P. F. Pope, and A. W. Stark. 2003. Research and development activity and expected returns in the United Kingdom. European Finance Review 7(1): 27-46.
3. Amir, E., and B. Lev. 1996. Value-relevance of non-financial information: The wireless communications industry. Journal of Accounting and Economics 22 (1): 3-30.
4. Arnum, P. V. 1999. The R&D race is on. Chemical Market Reporter 256: 3-8.
5. Barth, M. E., W. H. Beaver, J. R. M. Hand, and W. R. Landsman. 2004. Accruals, accounting-based valuation models, and the prediction of equity values. Working paper, Stanford University.
6. Barth, M., and S. Kallapur. 1996. The effects of cross-sectional scale differences on regression results in empirical accounting research. Contemporary Accounting Research 13 (2): 177-99
7. Bartov, E., P. Mohanram, and C. Seethamraju. 2002. Valuation of Internet stocks - An IPO perspective. Journal of Accounting Research 40 (2): 321-46.
8. Baum, J. A., T. Calabrese, B. S. Silverman. 2000. Don't go it alone: Alliance network composition and startups' performance in Canadian biotechnology. Strategic Management Journal 21 (3): 267-94.
9. Beatty, R., S. Riffe, and R. Thompson. 1999. The method of comparables and tax court valuations of private firms: An empirical investigation. Accounting Horizons 13 (3): 177-99.
10. Bhojraj, S., and C. M. C. Lee. 2002. Who is my peer? A valuation-based approach to the selection of firms. Journal of Accounting Research 40 (2): 407-39.
11. Campbell, J. 2000. Asset pricing at the millennium. The Journal of Finance 55 (4): 1515-67.
12. Chambers, D., R. Jennings, and R. B. Thompson. 2002. Excess returns to R&D intensive firms. Review of Accounting Studies 1 (2-3): 133-58.
13. Chan, L. K., J. Lakonishok, and T. Sougiannis. 2001. The stock market valuation of research and development expenditures. The Journal of Finance 56 (6): 2431-56.
14. Core, J. E., W. R. Guay, and A. Van Buskirk. 2003. Market valuations in the new economy: An investigation of what has changed. Journal of Accounting and Economics 34 (1-3): 43-67.
15. Courteau, L., J. L. Kao, T. O'Keefe, and G. D. Richardson. 2006. Relative accuracy and predictive ability of direct valuation models, PE models and a hybrid approach. Working paper, University of Toronto.
16. DiMasi, J. A. 1995. Success rate for new drug entering clinical testing in the United States. Clinical Pharmacology & Therapeutics 58 (1): 1-14.
17. DiMasi, J. A. 2001. New drug development in the United States from 1963 to 1999. Clinical Pharmacology & Therapeutics 69 (5): 286-96.
18. Easton, P. D., and G. A. Sommers. 2003. Scale and scale effect in market-based accounting research. Journal of Business Finance & Accounting 30 (1), 25-55.
19. Ely, K., P. J. Simko, and L. G. Thomas. 2003. The usefulness of biotechnology firms' drug development status in the development of research and development costs. Journal of Accounting, Auditing and Finance 18 (1): 163-96.
20. Financial Accounting Standards Board (FASB). 1974. Statement of Financial Accounting Standards (SFAS) No. 2: Accounting for research and development costs. Norwalk, CT: FASB.
21. Financial Accounting Standards Board (FASB). 1975. Statement of Financial Accounting Standards (SFAS) No. 7: Accounting and reporting by development stage enterprises. Norwalk, CT: FASB.
22. George, G., S. A. Zahra, K. W. Wheatley, and R. Khan. 2001. The effects of alliance portfolio characteristics and absorptive capacity on performance: A study of biotechnology firms. Journal of High Technology Management Research 12(2): 205-26.
23. Green, J. P., A. W. Stark, and H. M. Thomas. 1996. UK evidence on the market valuation of research and development expenditures. Journal of Business Finance & Accounting 23 (2): 191-216.
24. Guo, R., B. Lev, and N. Zhou. 2005. The valuation of biotech IPOs. Journal of Accounting, Auditing and Finance 20 (4): 423-59.
25. Hand, J. R. M. 2005. The value relevance of financial statements in the venture capital market. The Accounting Review 80 (2): 613-48.
26. Joos, P. 2002. Explaining the cross-sectional differences in market-to-book ratios in the pharmaceutical industry. Working paper, University of Rochester.
27. Kaitin, K. I. 2003. Post-approval R&D raises total drug development costs to $897 million. Tufts Center for the Study of Drug Development Impact Report 5 (3).
28. Keating, E. K., T. Z. Lys, and R. P. Magee. 2003. Internet downturn: Finding valuation factors in spring 2000. Journal of Accounting and Economics 34 (1-3): 189-236.
29. Kothari, S. P., T. E. Laguerre, and A. J.Leone. 2002. Capitalization versus expensing: Evidence on the uncertainty of future earnings from capital expenditures versus R&D outlays. Review of Accounting Studies 1 (4): 355-82.
30. Lev, B., B. Sarath, and T. Sougiannis. 2005. R&D reporting biases and their consequences. Contemporary Accounting Research 22 (4): 977-1026.
31. Lev, B., and T. Sougiannis. 1996. The capitalization, amortization, and value relevance of R&D. Journal of Accounting and Economics 21 (1): 107-38.
32. Lev, B., and T. Sougiannis. 1999. Penetrating the book-to-market black box: The R&D effect. Journal of Business Finance & Accounting 26 (3-4): 419-50.
33. Liu, J., D. Nissim, and J. Thomas. 2002. Equity valuation multiples. Journal of Accounting Research 40 (1): 135-72.
34. Ohlson, J. 1995. Earnings, book value, and dividends in equity valuation. Contemporary Accounting Research 11 (2): 661-87.
35. Penman, S. H. 1998. Combining earnings and book value in equity valuation. Contemporary Accounting Research 15 (3): 291-323.
36. Rajgopal, S., M. Venkatachalam, and S. Kotha. 2003. The value relevance of network advantages: The case of e-commerce firms. Journal of Accounting Research 41 (1): 135-63.
37. Richardson, G., and S. Tinaikar. 2004. Accounting based valuation models: What have we learned? Accounting and Finance 44 (2): 223-56.
38. Shevlin, T. 1996. The value-relevance of nonfinancial information: A discussion. Journal of Accounting and Economics 22 (1-3): 31-42.
39. Shores, D., and R. M. Bowen. 2002. Determinants of economic and accounting components of residual income: An application to the pharmaceutical industry. Working paper, University of Washington.
40. Shi, C. 2003. On the trade-off between the future benefits and riskiness of R&D: A bondholders' perspective. Journal of Accounting and Economics 35 (2): 227-54.
41. Sougiannis, T. 1994. The accounting based valuation of corporate R&D. The Accounting Review 69(1): 44-68.
42. Stuart, T. E. 2000. Interorganizational alliances and the performance of firms: A study of growth and innovation rates in a high-technology industry. Strategic Management Journal 21 (8): 791-811.
43. Theil, H. 1987. How many bits of information does an independent variable yield in a multiple regression. Statistics & Probability Letters 6 (2): 107-8.
44. Weintraub, A. 2004. Repairing the engines of life: Can research into stem cells and other advanced techniques heal ailing hearts and brains? Business Week, May 24, 98-106.